New trial aims to shield testicular cancer patients from Chemo-Induced hearing loss
NCT ID NCT07218913
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 25 times
Summary
This early-stage trial tests whether adding Pedmark to standard cisplatin chemotherapy can prevent hearing loss in men with testicular cancer that has spread. About 80% of patients currently develop hearing damage from cisplatin. Pedmark works by neutralizing harmful molecules caused by the chemo. The study will compare hearing outcomes between men who get Pedmark plus chemo and those who get chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEARING LOSS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.